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ABSTRACT 
Postnatal Betamethasone Decreases Respiratory Index in Ventilated Extremely Low Birth Weight Neonates 
Compared to Conventional Care 
Yuanyi Murray MD, Sanjeet Panda MBBS, Dina Finkel MD, Vanessa Mercado MD, Edmund F. LaGamma MD 
Division of Newborn Medicine, Department of Pediatrics, New York Medical College, Maria Fareri Children’s Hospital, Valhalla NY 10595 
 
Background 
   Bronchopulmonary dysplasia (BPD) is a major complication of 
ventilatory care and affects up to 50% of ELBW neonates.  A 2010 AAP 
Policy indicated that glucocorticoids may be considered for ELBWs on 
mechanical ventilation > 7 day postnatal age to abate progression of 
BPD. For > 16 years, we used postnatal BETA in lieu of dexamethasone 
or hydrocortisone to decrease ventilator support in high risk neonates 
because of its better safety profile (DeCastro, et al J Perinatol 29:297, 
2009). 
 
 
 
To determine whether low dose (0.125mg/kg IM), short course (every 24 
hours for 3 days) BETA between 7-30 days postnatal age would reduce 
the respiratory index in ELBWs vs. receiving conventional care (SRX, no 
steroid controls). 
 
 
 There’s a clinician selection bias to use BETA for sicker ELBWs. 
 There’s a significant short-term benefit of BETA in reducing the RI 
and FiO2 without increasing co-morbid complications. 
 There’s no decrease in ventilator days or BPD with administration of 
BETA. Long term neurodevelopmental evaluations are in progress. 
 We speculate that our clinicians selected patients with higher RI and 
FiO2 who may be too sick to lower BPD. 
 A prospective RCT is in progress. We seek to determine if low-dose 
betamethasone is a suitable alternative corticosteroid treatment for 
evolving BPD. 
FiO2, PIP, MAP and Respiratory Index at various time 
points between 7 days pre- & post- BETA (day of 
administration: 0) in BMZ and SRX groups. 
Demographics of ELBWs Why Betamethasone (BETA) ? 
 Antenatal  BETA has been associated with a decreased risk of cystic 
periventricular leukomalacia (PVL) when compared to dexamethasone 
or the absence of glucocorticoid therapy (Baud O et al., N Engl J Med 
1999; 341: 1190–1196) 
 Betamethasone has been used in pregnancy for over 20 years with an 
unprecedented high level of safety and efficacy.  
 The  CNS penetration of BETA is lower compared to dexamethasone 
because of lower lipid solubility and higher binding to serum proteins. 
(Trenque T et al., Fundam Clin Pharmacol 1994; 8: 430–436)  
 Single subcutaneous dose of 0.1 mg of BETA is 2- to 3- fold more 
potent than dexamethasone in accelerating fetal lung maturity without 
impairing fetal survival or weight gain and achieves lower peak than IV 
dose. (Christensen HD et al, . J Soc Gynecol Invest 1997; 4: 130–134) 
 
Methods 
 This is a  IRB approved, retrospective chart review from Jan 2013 – 
Dec 2015 of ELBWs who were intubated, ventilated and required FiO2 
> 0.35 between 7-30 day postnatal age.  Patients who received low 
dose BETA (0.125mg/kg IM Q24hr) for short duration (3d) were 
compared to a cohort who fulfilled entry criteria without BETA.  
 FiO2 and respiratory index (mean airway pressure x FiO2) were 
calculated at -7,-3,-1, 0,+1,+2,+3 and +7d after initiation of BETA along 
with demographics, respiratory variables and co-morbidities. 
 2-way repeated measures ANOVA was used for statistical analysis.  
Objective 
 Over the 3 year period of 247 ELBWs admitted, data analyzed include 
25 pts who received BETA and 26 controls. 
 From -7d to 0d, average FiO2 was unchanged in both groups. 
 At initiation of BETA, FiO2 was 0.67±0.24 & 0.45±0.16 (p<0.001) and 
RI was 7.5±3.5 & 4.1±1.9 (p=0.001) for BETA vs. control. 
 PIP, Respiratory Index (RI) and FiO2 decreased at +7d compared to 0d 
in BETA group (p=0.008 for PIP; p=0.02 for RI, p=0.03 for FiO2), but no 
change in the control group. 
 No significant difference in weight gain, hyperglycemia, uremia, iNO 
use, infection, or NEC between the groups.   
 Total number of ventilator days were 59±42d & 53±48d respectively 
and rate of BPD (O2 requirement at 36 weeks) were 88% (21/24) vs. 
77% (20/26); p=ns. 
Conclusion 
Results 
Tab-1:Patient Characteristics  
Using postnatal steroids in selective group of ELBWs 
Betamethasone 
(Mean+SD, n = 25) 
Control 
(Mean+SD, n = 26) 
Birth Weight (grams) 698.2 ± 167.7 717.7 ± 145.2 
Gestation (wks) 24.5 ± 1.2 25.3 ± 1.5 
Male 56%(14/25) 54%(14/26) 
BETA (DOL) 19.7 ± 6.3 none 
Apgars <6 at 5 mins 60% (15/25) 42% (11/26) 
Antenatal steroid 80% (20/25) 77% (20/26) 
IUGR 12% (3/25) 8% (2/26) 
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Betamethasone 
(Mean+SD, n = 25) 
Control 
(Mean+SD, n = 26) 
Weight Gain              Pre-BETA                       
(gm/kg/d) 17.5 ± 12.8 17.0 ± 11.9 
                      Post-BETA 
(gm/kg/d) 12.5 ± 12.8 15.6 ± 13.5 
Bld Glucose (max)  Pre-1week 157.4 ± 45.7 179.7 ± 48.3 
                                Post-1week 148.2 ± 45.5 118.9 ± 37.0 
BPD 88% (21/24) 77% (20/26) 
Ventilator days 59 ± 42 53 ± 48 
EUGR at disposition 16% (4/25) 31% (8/26) 
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